GleamWall
中文EN

VKTX Viking Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1607678 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-164.2%
TTM EPS YoY-155.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-96.4%
ROA-73.1%
ROIC (approx.)-195.7%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets39.8%
Debt / equity0.00x
Current ratio7.27x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-19.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$0$0
R&D expense$166.80M$115.75M$150.15M$153.46M$89.95M$60.15M$41.39M$30.99M
SG&A expense$20.31M$16.84M$13.97M$11.28M$8.61M$14.42M$14.08M$15.25M
Operating income-$187.11M-$132.60M-$164.12M-$164.74M-$98.56M-$74.57M-$55.47M-$46.24M
Interest expense$88,000———$0———
Net income-$183.19M-$128.02M-$158.32M-$157.66M-$90.79M-$65.56M-$45.63M-$35.42M
EPS (basic)-1.55-1.10-1.37—-0.81-0.58-0.41—
EPS (diluted)-1.55-1.10-1.37—-0.81-0.58-0.41—
Weighted avg. shares (diluted)118.05M116.26M115.57M—112.32M112.13M112.07M—
Balance sheet
Cash & equivalents$677.61M$125.75M$118.12M$165.81M$100.38M$33.88M$37.94M$26.68M
Short-term investments$282.20M$375.91M$484.85M$539.93M$614.19M$773.84M$813.92M$875.94M
Current assets$973.00M$517.56M$608.21M$715.60M$738.70M$827.02M$866.02M$907.22M
Total assets$977.17M$521.90M$608.24M$715.73M$739.41M$827.85M$866.99M$908.32M
Current liabilities$133.90M$109.66M$106.33M$76.67M$26.07M$31.98M$19.57M$27.41M
Total liabilities$388.57M$113.58M$106.33M$76.67M$26.39M$32.39M$20.07M$28.04M
Shareholders' equity$588.60M$408.32M$501.92M$639.06M$713.03M$795.46M$846.92M$880.28M
Shares outstanding127.52M116.65M115.89M114.79M112.45M112.33M112.29M111.57M
Cash flow statement
Operating cash flow-$138.19M-$125.17M-$113.98M-$85.29M-$94.00M-$47.06M-$52.33M-$31.18M
Investing cash flow$92.52M$109.43M$54.19M$75.61M$160.03M$42.51M$63.24M$6.58M
Financing cash flow$597.55M$23.59M$12.08M$75.10M$480,000$507,000$349,000$1.00M
Stock-based compensation$17.89M$11.13M$10.34M$8.59M$7.34M$13.55M$11.35M$5.67M

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.